Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To describe the prevalence and causes of clinically detectable uveitic serous retinal detachment (SRD).
Methods: Retrospective chart review of a large clinic-based series.
Results: Serous retinal detachment was present in 78 of the 2761 (2.8%) patients. Vogt-Koyanagi-Harada (VKH) disease was the most commonly identified cause (38/78, 48.7%). Less common associated etiologies included toxoplasmic retinochoroiditis (8/78, 10.3%), sarcoidosis (5/78, 6.4%), intraocular lymphoma (4/78, 5.1%), presumed tuberculosis (3/78, 3.8%), and posterior scleritis (2/78, 2.6%). Fifteen patients (19.2%) with uveitic SRD at presentation had no identifiable etiology and were labeled idiopathic or indeterminant. Thirty of the 38 patients with VKH disease (78.9%) had positive neurological and/or integumentary findings, and therefore constituted either complete or incomplete subtypes of the disease. The remaining eight (21.1%) had presumed/ocular VKH disease limited to the eye.
Conclusion: While VKH disease by far is the most common cause of clinically detectable uveitic SRD, a number of other non-infectious and infectious inflammatory disorders were also associated with this distinctive clinical finding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1120672121991391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dynamics of color vision recovery in Vogt-Koyanagi-Harada disease: a longitudinal study using cone contrast test and adaptive optics imaging.
J Ophthalmic Inflamm Infect
August 2025
Department of Ophthalmology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Background: Vogt-Koyanagi-Harada (VKH) disease affects visual function, but the recovery process of color vision remains incompletely understood. This study aimed to assess color vision recovery in VKH using cone contrast testing and explore its relationship with cone cell density measured using adaptive optics imaging.
Methods: Twenty-two eyes of 11 patients with VKH were evaluated at baseline (serous retinal detachment resolution) and at 3, 6, and 12 months post-treatment.
Ultrawidefield Optical Coherence Tomography Angiography in the Mid-Periphery and Macula of Vogt-Koyanagi-Harada Disease.
Ocul Immunol Inflamm
August 2025
Ophthalmologic Center of the Second Hospital, Jilin University, Changchun, P.R. China.
Purpose: To investigate ultrawidefield optical coherence tomography angiography (UWF-OCTA) changes in the mid-periphery of new-onset active Vogt-Koyanagi-Harada (VKH) patients.
Methods: New-onset and untreated active VKH patients were continuously observed using UWF-OCTA at 2 weeks, 1, and 3 months after treatment.
Results: Twenty-four new-onset and untreated active VKH patients were included.
Acute phase Vogt-Koyanagi-Harada syndrome resistant to corticosteroid therapy in an adult female patient.
Arch Soc Esp Oftalmol (Engl Ed)
August 2025
Department of Ophthalmology, Faculty of Medicine, Mersin University, Mersin, Turkey.
Vogt-Koyanagi-Harada (VKH) syndrome is a rare inflammatory disease that affects more than one system, including ophthalmological, auditory, cutaneous, and neurological systems. VKH syndrome is mostly characterized by panuveitis with serous retinal detachment, headache, hearing loss, vitiligo, and poliosis. Early diagnosis and proper management are crucial to prevent irreversible visual loss and other complications.
View Article and Find Full Text PDFClinical characteristics and visual outcome of Vogt Koyanagi Harada disease patients in a specialized eye hospital in Nepal.
J Nepal Health Res Counc
June 2025
Department of Uveitis, Tilganga Institute of Ophthalmology, Gaushala, Kathmandu, Nepal.
Background: To evaluate clinical characteristics and visual outcome of Vogt-Koyanagi-Harada disease patients in Nepal.
Methods: Retrospective series of all the cases of VKH treated at Tilganga Institute of Ophthalmology from 1st July 2017 to 31st June 2022.
Results: Fifty-four cases were included, 18(33.
Clinical features, treatment and outcomes of dabrafenib-associated uveitis.
Invest New Drugs
July 2025
College of Pharmacy, Changsha Medical University, Changsha, 410219, Hunan, China.
Background: To explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment.
Methods: The database was retrieved to collect reports of dabrafenib-associated uveitis and clinical data were collected for retrospective analysis.
Results: Twenty-six patients were included in the study, with a median age of 56 years (range 30, 75).